These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 28181220)

  • 1. Eslicarbazepine acetate as adjunctive therapy in clinical practice: ESLADOBA study.
    Chaves J; Breia P; Pimentel J; Pelejão R; Carvalho M; Mateus P; Grebe H; Mestre A; Fernandes H; Sousa R; Gala A
    Acta Neurol Scand; 2017 Nov; 136(5):407-413. PubMed ID: 28181220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world data on eslicarbazepine acetate as add-on to antiepileptic monotherapy.
    Holtkamp M; McMurray R; Bagul M; Sousa R; Kockelmann E
    Acta Neurol Scand; 2016 Jul; 134(1):76-82. PubMed ID: 26915469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study.
    Elger C; Halász P; Maia J; Almeida L; Soares-da-Silva P;
    Epilepsia; 2009 Mar; 50(3):454-63. PubMed ID: 19243424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-year follow-up with eslicarbazepine acetate: a consecutive, retrospective, observational study.
    Correia FD; Freitas J; Magalhães R; Lopes J; Ramalheira J; Lopes-Lima J; Chaves J
    Epilepsy Res; 2014 Oct; 108(8):1399-405. PubMed ID: 25060997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of eslicarbazepine acetate monotherapy for partial-onset seizures: Experience from a multicenter, observational study.
    Toledano R; Jovel CE; Jiménez-Huete A; Bayarri PG; Campos D; Gomariz EL; Giráldez BG; García-Morales I; Falip M; Agredano PM; Palao S; Prior MJAA; Pascual MRQ; Navacerrada FJ; González FJL; Ojeda J; Sáez AA; Bermejo PE; Gil-Nagel A
    Epilepsy Behav; 2017 Aug; 73():173-179. PubMed ID: 28641170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eslicarbazepine acetate: a review of its use as adjunctive therapy in refractory partial-onset seizures.
    Keating GM
    CNS Drugs; 2014 Jul; 28(7):583-600. PubMed ID: 24972948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of eslicarbazepine-acetate in elderly patients with focal epilepsy: Case series.
    Gómez-Ibáñez A; Serratosa JM; Guillamón E; Garcés M; Giráldez BG; Toledo M; Salas-Puig J; López-González FJ; Rodríguez-Uranga J; Castillo A; Mauri JA; Camacho JL; López-Gomáriz E; Giner P; Torres N; Palau J; Molins A; Villanueva V
    Seizure; 2017 May; 48():53-56. PubMed ID: 28419947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Eslicarbazepine acetate in clinical practice. Efficacy and safety results].
    Serrano-Castro PJ; Payán-Ortiz M; Cimadevilla JM; Quiroga-Subirana P; Fernández-Pérez J
    Rev Neurol; 2013 Mar; 56(6):309-14. PubMed ID: 23483464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study.
    Jacobson MP; Pazdera L; Bhatia P; Grinnell T; Cheng H; Blum D;
    BMC Neurol; 2015 Mar; 15():46. PubMed ID: 25880756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of eslicarbazepine acetate as adjunctive therapy for refractory focal-onset seizures in children: A double-blind, randomized, placebo-controlled, parallel-group, multicenter, phase-III clinical trial.
    Kirkham F; Auvin S; Moreira J; Gama H; Falcão AC; Rocha JF; Soares-da-Silva P
    Epilepsy Behav; 2020 Apr; 105():106962. PubMed ID: 32151803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjunctive eslicarbazepine acetate: A pooled analysis of three phase III trials.
    Biton V; Rogin JB; Krauss G; Abou-Khalil B; Rocha JF; Moreira J; Gama H; Trinka E; Elger CE; Cheng H; Grinnell T; Blum D;
    Epilepsy Behav; 2017 Jul; 72():127-134. PubMed ID: 28575761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eslicarbazepine acetate add-on for drug-resistant partial epilepsy.
    Chang XC; Yuan H; Wang Y; Xu HQ; Zheng RY
    Cochrane Database Syst Rev; 2011 Dec; (12):CD008907. PubMed ID: 22161441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EARLY-ESLI study: Long-term experience with eslicarbazepine acetate after first monotherapy failure.
    Villanueva V; Bermejo P; Montoya J; Toledo M; Gómez-Ibáñez A; Garcés M; Vilella L; López-González FJ; Rodriguez-Osorio X; Campos D; Martínez P; Giner P; Zurita J; Rodríguez-Uranga J; Ojeda J; Mauri JA; Camacho JL; Ruiz-Giménez J; Poza JJ; Massot-Tarrús A; Galiano ML; Bonet M
    Acta Neurol Scand; 2017 Sep; 136(3):254-264. PubMed ID: 27935017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ROME (Retrospective Observational Multicenter study on Eslicarbazepine) study: Efficacy and behavioural effects of Eslicarbazepine acetate as adjunctive therapy for adults with partial onset seizures in real life.
    Assenza G; Mecarelli O; Lanzone J; Assenza F; Tombini M; Di Lazzaro V; Pulitano P
    Seizure; 2018 May; 58():35-40. PubMed ID: 29649684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and efficacy following conversion to eslicarbazepine acetate monotherapy in adults with focal seizures.
    Chung S; Sinha SR; Shah A; Stern JM; Cheng H; Jung J; Grinnell T; Blum D
    Epilepsy Res; 2019 Jul; 153():59-65. PubMed ID: 30999260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures.
    Gil-Nagel A; Lopes-Lima J; Almeida L; Maia J; Soares-da-Silva P;
    Acta Neurol Scand; 2009 Nov; 120(5):281-7. PubMed ID: 19832771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy.
    Ben-Menachem E; Gabbai AA; Hufnagel A; Maia J; Almeida L; Soares-da-Silva P
    Epilepsy Res; 2010 May; 89(2-3):278-85. PubMed ID: 20299189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eslicarbazepine acetate in post-stroke epilepsy: Clinical practice evidence from Euro-Esli.
    Sales F; Chaves J; McMurray R; Loureiro R; Fernandes H; Villanueva V
    Acta Neurol Scand; 2020 Dec; 142(6):563-573. PubMed ID: 32691850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations between seizure severity change and patient characteristics, changes in seizure frequency, and health-related quality of life in patients with focal seizures treated with adjunctive eslicarbazepine acetate: Post hoc analyses of clinical trial results.
    Cramer JA; Colman S; Anastassopoulos KP; Grinnell T; Mehta D; Williams GR
    Epilepsy Behav; 2020 Nov; 112():107312. PubMed ID: 32801102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time to baseline seizure count in patients with focal seizures receiving adjunctive eslicarbazepine acetate in a phase IV clinical trial.
    Aboumatar S; Krishnaiengar SR; Cantu D; Zhang Y; Grinnell T
    Clin Neurol Neurosurg; 2023 Feb; 225():107552. PubMed ID: 36657359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.